M. Kowalski

发表

The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors

Jennifer R. Brown, J. Cizeau, J. Entwistle, 2013 .

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis

R. Laborde, A. Leontovich, A. Tefferi, 2013, Leukemia.

Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial

P. Horby, J. Whitehead, A. Rojek, 2016, PLoS medicine.

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients

J. Cizeau, J. Entwistle, G. Macdonald, 2010, Drug design, development and therapy.

The Preclinical and Clinical Evaluation of VB 6-845 : An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors

Jennifer R. Brown, J. Cizeau, J. Entwistle, 2013 .

A soluble CD4 protein selectively inhibits HIV replication and syncytium formation

R. Siliciano, B. Walker, E. Reinherz, 1988, Nature.

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic.

A. Mead, S. Verstovsek, R. Mesa, 2021, Future oncology.

ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial.

Angela G. Fleischman, M. Arcasoy, T. Ganz, 2020, Blood advances.

A Pharmacokinetic Analysis of Diclofenac Potassium Soft-Gelatin Capsule in Patients After Bunionectomy

M. Kowalski, Keith A. Moore, C. Bon, 2010, American journal of therapeutics.

An Expanded Multicenter Phase I/II Study of CYT387, a JAK- 1/2 Inhibitor for the Treatment of Myelofibrosis,

A. Roberts, M. Wadleigh, A. Tefferi, 2011 .

Perspectives of Policymakers on the Introduction and Scale-Up of HIV Self-Testing and Implication for National HIV Programming in Ghana

W. Tun, M. Kowalski, S. A. Addo, 2021, Frontiers in Public Health.

Attenuation of human immunodeficiency virus type 1 cytopathic effect by a mutation affecting the transmembrane envelope glycoprotein

J. Sodroski, W. Haseltine, L. Bergeron, 1991, Journal of virology.

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

S. Verstovsek, R. Mesa, F. Passamonti, 2020 .

Single-dose pharmacokinetic study of rapidly dispersing diclofenac potassium formulations in healthy volunteers

M. Kowalski, Keith A. Moore, D. Stiff, 2009, Current medical research and opinion.

High level of surface CD4 prevents stable human immunodeficiency virus infection of T-cell transfectants

R. Finberg, D. Diamond, M. Kowalski, 1992, Journal of virology.

HIV ENVELOPE-CD4 INTERACTION NOT INHIBITED BY SYNTHETIC OCTAPEPTIDES

W. Haseltine, C. Rosen, M. Kowalski, 1987, The Lancet.

Cis-acting sequences responsive to the rev gene product of the human immunodeficiency virus.

J. Sodroski, W. Haseltine, E. Terwilliger, 1988, Journal of acquired immune deficiency syndromes.

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

M. Spearman, J. Cizeau, J. Entwistle, 2008, Drug design, development and therapy.

Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants

J. Sodroski, U. Olshevsky, W. Haseltine, 1990, Journal of virology.

Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.

B. Walker, J. Sodroski, M. Krieger, 1987, Proceedings of the National Academy of Sciences of the United States of America.

Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

J. Sodroski, W. Haseltine, C. Rosen, 1987, Science.

A phase I study of VB6-845, an anti-EpCAM fusion protein targeting advanced solid tumours of epithelial origin: preliminary results

G. Macdonald, M. Kowalski, M. Rasamoelisolo, 2008 .

A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin.

M. Jewett, J. Cizeau, J. Entwistle, 2012, The Journal of urology.

A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck

M. Spearman, J. Entwistle, G. Macdonald, 2009, Medical oncology.

A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer

J. Neal, H. Wakelee, J. Kawashima, 2021, Cancer Chemotherapy and Pharmacology.

Antibodies to CD4 in individuals infected with human immunodeficiency virus type 1.

J. Sodroski, W. Haseltine, D. Blohm, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.

S. Baruchel, M. Yalon, Jeffrey C. Allen, 2014, Neuro-oncology.

Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome

F. Giles, G. Roboz, M. Schuster, 2006, Leukemia.

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

A. Roberts, M. Wadleigh, A. Tefferi, 2012 .

Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis.

A. Roberts, A. Tefferi, D. Caramazza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects on CD4 binding of anti-peptide sera to the fourth and fifth conserved domains of HIV-1 gp120.

J. Sodroski, W. Haseltine, J. Bristol, 1990, Journal of acquired immune deficiency syndromes.

A phase I/II study of TKM-080301, a PLK1-targeted RNAi in patients with adrenocortical cancer (ACC).

David C. Smith, J. Carpten, W. Liang, 2016 .

A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer

R. Plummer, U. Banerji, L. Carter, 2023, British Journal of Cancer.

Update On The Long-Term Efficacy and Safety Of Momelotinib, a JAK1 and JAK2 Inhibitor, For The Treatment Of Myelofibrosis

A. Roberts, M. Wadleigh, A. Tefferi, 2013 .

Role of the human immunodeficiency virus type I envelope glycoprotein in cytopathic effect.

J. Sodroski, W. Haseltine, M. Kowalski, 1991, Advances in experimental medicine and biology.

A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.

U. Banerji, H. Arkenau, L. Carter, 2019, Journal of Clinical Oncology.

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer.

R. Plummer, U. Banerji, V. Moreno, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Antibodies to CD 4 in individuals infected with human immunodeficiency virus type 1

J. Sodroski, W. Haseltine, D. Blohm, 2022 .

A phase I clinical study of VB4-845: Weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck

M. Spearman, J. Cizeau, J. Entwistle, 2008, Drug design, development and therapy.

A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin.

M. Jewett, J. Cizeau, J. Entwistle, 2012, The Journal of urology.